Table 4.

Significant correlations of clinical features with plasma cytokine and chemokine levels in localized scleroderma patients (n = 69)

	Cytokine	Spearman’s rho	p	*corrected p
Disease Activity Measure
PGA-A	IP-10 ‡	0.45	<0.001	0.005
	TNF-α	0.31	0.012	0.167
	IL-8	0.28	0.023	0.167
	GM-CSF	0.28	0.023	0.167
mLoSSI	IP-10	0.34	0.004	0.130
	TNF-α	0.29	0.018	0.187
	IL-8	0.25	0.038	0.187
	IL-10	0.26	0.031	0.187
	IL-13	0.24	0.049	0.187
	IL-lβ	0.25	0.045	0.187
Disease Damage Measure
PGA-D	No significant correlations
LoSDI	IL-17a	−0.31	0.011	0.190
	IL-4	−0.29	0.019	0.190
	IL-6	−0.28	0.020	0.190
	IL-17f	−0.27	0.030	0.197
Patient Assessment Measure
Parent-GA	IP-10 ‡	0.40	0.002	0.042
	IL-5 ‡	0.38	0.003	0.042
	IL-12 ‡	0.36	0.004	0.043
	IL-13	0.32	0.014	0.086
	IL-2	0.31	0.015	0.086
Patient-GA	IP-10	0.31	0.016	0.451
CDLQI	IL-12	0.29	0.040	0.400
	IL-8	0.28	0.045	0.400

^*corrected for False Discovery Rates (FDR) by Benjamini-Hochberg (B–H) method

^‡significant after B-H correction

PGA-A, Physician global assessment of activity; mLoSSI, modified Localized Scleroderma Skin Score; PGA-D, Physician Global Assessment of Damage; LoSDI, Localized Scleroderma Damage Index; Parent-GA, parent Global Assessment of disease impact; Patient-GA, patient Global Assessment of disease impact; CDLQI, Childhood Dermatology Life Quality Index